• Increase font size
  • Default font size
  • Decrease font size
home | about us | contact us
Search
Search Only:

Search Keyword fda calendar extreme

Total: 50 results found.

... BioThrax® BioThrax is the only FDA-licensed vaccine for the prevention of anthrax infection. It is indicated for the active immunization of adults who are at high risk of exposure to anthrax. BioThrax ...
... program to resolve the sole remaining chemistry, manufacturing & control (CMC) issue necessary to potentially gain FDA marketing approval for Surfaxin(R) (lucinactant) for the prevention of Respiratory ...
... in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here: http://biomedreports.com/fda-calendar/fda-calendar.html About BioMedReports.Com BioMedReports.com ...
... now at BioMedReports.Com Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here: http://biomedreports.com/fda-calendar/fda-calendar.html ...
The BioMedReports.com FDA Calendar database includes over 350 entries of (1) pending new drug, biological agent, or medical device new product decisions at the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, and ...
...  "Why wasn't VRMLQ on your FDA Calendar as one of the companies to invest in?" "How could you guys miss this?" We had omitted the company because we would never knowingly advise anyone to invest in ...
7. A New Drug Delivery, Diabetes Monitoring Extreme Trade
(Premium Content/Subscriber Only Content)
Below is a new entry to the BioMedReports.com FDA Calendar database that represents an extreme trade on an innovative system for blood glucose monitoring for diabetics, in addition to a drug delivery system. ...
...  Peregrine will begin reverse stock split on Monday FDA Calendar Extreme Trades: 85 Single Digit Stocks Preliminary data at the end of the six planned treatment cycles in the Phase II ...
... MucoAdhesive) Film Technology, while seeking FDA approval through the 505(b)(2) pathway, which represents a lower risk / cost and quicker route to commercialization as compared to the process of developing ...
... the most recent corporate presentation for IntelGenx (IGXT.OB) (IGX.V), including the following update below on its pending FDA decision for a novel, once-daily 450 mg formulation of the widely used anti-depressant ...
... (sNDA) to the FDA and an Extension Application to the European Medicines Agency (EMEA) for RELISTOR (methylnaltrexone bromide) subcutaneous injection for a new delivery system, pre-filled syringes. RELISTOR ...
The BioMedReports.com FDA Calendar database includes over 400 entries of (1) pending new drug, biological agent, or medical device new product decisions at the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, and ...
13. FDA Calendar Extreme Trades: 85 Single Digit Stocks
(Premium Content/Subscriber Only Content)
The BioMedReports.com FDA Calendar database includes over 400 entries of (1) pending new drug, biological agent, or medical device new product decisions at the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, and ...
... play on the FDA Calendar Extreme Trade series which is leveraged to the commercial success / targeted marketing of new medical products, devices, and diagnostics. In addition, the nature of early-stage ...
... LE-DT. The first study will be conducted in hormone refractory metastatic prostate cancer patients and the protocol for this study had been submitted to FDA for review.  The Company expects to enroll 40 ...
...  Products *All information taken from company website orBec® GVHD Treatment Their main product, the only Phase III for the past six months, which also has obtained the illustrious FDA Oprhan ...
Discovery Laboratories, Inc. (Nasdaq:DSCO) has received written notification from the U.S. Food and Drug Administration (FDA) that a meeting has been scheduled for September 29, 2009. This meeting will ...
18. FDA Calendar Updates: Delcath, Pozen, Advanced Life Sciences
(Premium Content/Subscriber Only Content)
Below are updates to the BioMedReports.com FDA Calendar, which includes a database of 353 entries as of 8/31/09. The calendar was originally created by Mike Havrilla to track companies with pending new ...
19. DepoMed: A Drug Delivery, Dual Trial Extreme Trade
(Premium Content/Subscriber Only Content)
Below are updates to the BioMedReports.com FDA Calendar, which includes a database of 349 entries as of 8/28/09. The calendar was originally created by Mike Havrilla to track companies with pending new ...
20. Derma Sciences: A Wound Care Extreme Trade
(Premium Content/Subscriber Only Content)
Below are updates to the BioMedReports.com FDA Calendar, which includes a database of 347 entries as of 8/28/09. The calendar was originally created by Mike Havrilla to track companies with pending new ...
21. Medicago: Early-Stage Extreme Trade on Pandemic Flu Vaccine
(Premium Content/Subscriber Only Content)
Below are updates to the BioMedReports.com FDA Calendar, which includes a database of 346 entries as of 8/27/09. The calendar was originally created by Mike Havrilla to track companies with pending new ...
Below are updates to the BioMedReports.com FDA Calendar, which includes a database of 343 entries as of 8/25/09. The calendar was originally created by Mike Havrilla to track companies with pending new ...
23. FDA Calendar Extreme Trade Update: Cardium
(Premium Content/Subscriber Only Content)
Below are updates to the BioMedReports.com FDA Calendar, which includes a database of 342 entries as of 8/25/09. The calendar was originally created by Mike Havrilla to track companies with pending new ...
24. New Extreme Trade: Vicor Technologies (VCRT.OB)
(Premium Content/Subscriber Only Content)
Below are updates to the BioMedReports.com FDA Calendar, which includes a database of 342 entries as of 8/25/09. The calendar was originally created by Mike Havrilla to track companies with pending new ...
... false negatives.  Eventual commercial level accuracy in the 90% range is to be reasonably expected compared to PAP staining which is 64% accurate.  Biomoda submitted a Pre-IDE to the FDA who responded ...
26. Nutra Pharma (OTC: NPHC): New FDA Calendar Extreme Trade
(Premium Content/Subscriber Only Content)
... test kits for infectious diseases, including Tuberculosis and NonTuberculous Mycobacteria (NTM). NPHC.OB expects to complete research and complete a regulatory submission to the FDA during 4Q09, which ...
27. Two New FDA Calendar Extreme Trades: CERS, EDAP
(Premium Content/Subscriber Only Content)
Below are updates to the BioMedReports.com FDA Calendar, which includes a database of 325 entries as of 8/19/09. The calendar was originally created by Mike Havrilla to track companies with pending new ...
28. FDA Calendar Updates: BioElectronics (BIEL.PK)
(Premium Content/Subscriber Only Content)
Below are updates to the BioMedReports.com FDA Calendar, which includes a database of 324 entries as of 8/19/09. The calendar was originally created by Mike Havrilla to track companies with pending new ...
29. FDA Calendar Updates: Three New Extreme Trades
(Premium Content/Subscriber Only Content)
Below are updates to the BioMedReports.com FDA Calendar, which includes a database of 316 entries as of 8/14/09. The calendar was originally created by Mike Havrilla to track companies with pending new ...
30. FDA Calendar Extreme Trades: 40 Stocks Under $5
(Premium Content/Subscriber Only Content)
Below are extreme trades among 40 companies with stock prices under $5 from the BioMedReports.com FDA Calendar, which includes 310 entries as of 8/12/09. The calendar was originally created by Mike Havrilla ...
Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of 299 entries as of 8/3/09. The calendar was originally created by Mike Havrilla to track companies with ...
Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of 298 entries as of 8/3/09. The calendar was originally created by Mike Havrilla to track companies with ...
Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of 297 entries as of 8/3/09.. The calendar was originally created by Mike Havrilla to track companies with ...
Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of 297 entries as of 8/3/09.. The calendar was originally created by Mike Havrilla to track companies with ...
Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of 298 entries as of 8/3/09. The calendar was originally created by Mike Havrilla to track companies with ...
Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of 299 entries as of 8/3/09. The calendar was originally created by Mike Havrilla to track companies with ...
Below are extreme trades among 30 companies with stock prices under $5 from the BioMedReports.com FDA Calendar, which includes 292 entries as of 8/1/09. The calendar was originally created by Mike Havrilla ...
Below are extreme trades among 30 companies with stock prices under $5 from the BioMedReports.com FDA Calendar, which includes 292 entries as of 8/1/09. The calendar was originally created by Mike Havrilla ...
Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of 288 entries as of 7/30/09. The calendar was originally created by Mike Havrilla to track companies with ...
Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of 288 entries as of 7/30/09. The calendar was originally created by Mike Havrilla to track companies with ...
Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of 284 entries as of 7/28/09. The calendar was originally created by Mike Havrilla to track companies with ...
Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of 284 entries as of 7/28/09. The calendar was originally created by Mike Havrilla to track companies with ...
Below is a summary of updates and new extreme trades included in the BioMedReports.com FDA Calendar, which includes a database of 280 entries as of 7/23/09. The calendar was originally created by Mike ...
DALLAS-- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), announced today that its European partner, SpePharm, is collecting data from a post approval study of MuGard in head and neck cancer patients ...
Below is a summary of updates and new extreme trades included in the BioMedReports.com FDA Calendar, which includes a database of 280 entries as of 7/23/09. The calendar was originally created ...
... with the approval by the U.S. Food and Drug Administration (FDA) of BDSI’s breakthrough cancer pain product ONSOLIS™ (fentanyl buccal soluble film) and satisfactory preparation of commercial ...
Below are extreme trades among 20 companies with stock prices under $5 from the BioMedReports.com FDA Calendar, which includes 264 entries as of 7/20/09. The calendar was originally created by Mike Havrilla ...
... in collaboration with GSK and leading international SLE experts, and the program is being conducted under a Special Protocol Assessment agreement with FDA. The primary efficacy endpoint of BLISS-52 and ...
Below are extreme trades among 20 companies with stock prices under $5 from the BioMedReports.com FDA Calendar, which includes 264 entries as of 7/20/09. The calendar was originally created by Mike Havrilla ...
... quarter of 2008, the Company completed a multiple ascending dose human tolerability Phase I clinical trial of ORE1001 under an Investigative New Drug Application (“IND”) filed with the FDA ...

Get Free Email and Phone News Alerts

* Your email address:
* Preferred Format:
* Enter the security code shown:
 
Home | Privacy Policy
© 2010 BioMedReports.com. All rights reserved